Affymetrix Beats Ests., Posts Loss - Analyst Blog
May 08 2012 - 7:30AM
Zacks
Affymetrix Inc.
(AFFX), a global genetic products company, reported first quarter
fiscal 2012 adjusted (excluding one-time expenses) loss of 6 cents
per share, better than the Zacks Consensus Estimate of a loss of 9
cents a share and lower than the year-ago breakeven situation.
Loss in the reported quarter was
$4.2 million (or loss of 6 cents per share) versus a profit of
$0.04 million in the year-ago quarter, primarily due to lower
sales.
Revenues
Revenues dropped 11.5% year over
year to $65.2 million, marginally ahead of the Zacks Consensus
Estimate of $65 million. Sales dropped mainly due to poor
consumable sales.
Revenues from products dipped 13.3%
year over year to $58.5 million in the first quarter, which
included consumable sales of $53.7 million, down 14.6%. However,
instrument sales inched up 2.2% to $4.7 million. Services and other
revenues improved 9.7% year over year to $6.8 million.
Margins
Gross margin fell to 58.1% in the
quarter from 63.2% a year ago, hurt by lower sales. This was
partially offset by lower warranty expense and a decline in excess
and obsolescence costs in inventory. Product gross margin declined
to 59.7% from 64.6% in the prior-year quarter.
Operating loss was $3.4 million in
the quarter compared with an income of $3.1 million, a year-ago.
Selling, general and administrative (SG&A) expenses were 42.8%
of sales versus 36.9% in the year-ago quarter. Research and
Development (R&D) expenses, as a percentage of sales, fell
slightly to 20.4% from 22.1% in the year-ago period.
Balance Sheet
Affymetrix ended first quarter 2012
with cash and cash equivalents and available for sale securities
(short-term) of $119.2 million, up 45.7% year over year. There were
no outstanding convertible notes at the end of the quarter.
Our Take
Affymetrix is a leading provider of
microarray-based products and services to the global research
community. Along with Illumina Inc. (ILMN), it is
one of the two major providers of microarray technologies,
primarily used in the field of genetic research. Affymetrix holds a
leading position in the gene expression products and services
market.
Affymetrix is expanding its
customer base through new product launches and strategic alliances.
Moreover, the company is pursuing a number of strategies (including
expansion into new markets) aimed at expanding its top line. The
company entered into a deal with pharma services major, Almac Group
Ltd.in the reported quarter to distribute Almac’s Xcel microarray
products globally.
Affymetrix is shifting its R&D
focus from discovery and exploration markets to the faster-growing
validation and routine testing markets. The company reckons
cytogenetics and cancer research as promising areas for expansion,
representing market opportunities of roughly $200 million and $500
million, respectively.
The company has realigned its
operation into a number of business units including gene
expression, genetic analysis, life science reagents and clinical
diagnostics. The structural changes are expected to streamline its
decision-making process while improving customer focus and
accountability.
Affymetrix has also taken up
various steps to stabilize its expression business. Moreover, the
company expects its genetic analysis and clinical diagnostic
business to grow briskly in 2012, driven by its cytogenetics
program and increased traction of its Axiom genotyping platform.
The company recently launched its Axiom Exome Genotyping Arrays in
the market.
We are also encouraged by the
company’s move to buy privately-held eBioscience, a global leader
in immunology and oncology flow cytometry reagents. The acquisition
will significantly boost its foothold in the fast-growing
immunology, oncology and translational medicine markets,
representing an annual opportunity nearing $3 billion.
However, Affymetrix is operating in
an intensely competitive industry and faces risks associated with
lower R&D spending by its customers due to a soft economy and
government actions including budget cuts.
Affymetrix is exposed to a volatile
funding environment. The company has been beset by uncertainties
surrounding National Institutes of Health (“NIH”) funding. Decline
in government research grants may substantially affect the
company’s revenues.
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
ILLUMINA INC (ILMN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024